IBDEI16X ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20240,2)
 ;;=^5063349
 ;;^UTILITY(U,$J,358.3,20241,0)
 ;;=Z80.43^^84^930^40
 ;;^UTILITY(U,$J,358.3,20241,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20241,1,3,0)
 ;;=3^Family Hx of Malig Neop of Testis
 ;;^UTILITY(U,$J,358.3,20241,1,4,0)
 ;;=4^Z80.43
 ;;^UTILITY(U,$J,358.3,20241,2)
 ;;=^5063350
 ;;^UTILITY(U,$J,358.3,20242,0)
 ;;=Z80.6^^84^930^32
 ;;^UTILITY(U,$J,358.3,20242,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20242,1,3,0)
 ;;=3^Family Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,20242,1,4,0)
 ;;=4^Z80.6
 ;;^UTILITY(U,$J,358.3,20242,2)
 ;;=^5063354
 ;;^UTILITY(U,$J,358.3,20243,0)
 ;;=Z80.8^^84^930^37
 ;;^UTILITY(U,$J,358.3,20243,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20243,1,3,0)
 ;;=3^Family Hx of Malig Neop of Organs/Systems
 ;;^UTILITY(U,$J,358.3,20243,1,4,0)
 ;;=4^Z80.8
 ;;^UTILITY(U,$J,358.3,20243,2)
 ;;=^5063356
 ;;^UTILITY(U,$J,358.3,20244,0)
 ;;=Z81.8^^84^930^42
 ;;^UTILITY(U,$J,358.3,20244,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20244,1,3,0)
 ;;=3^Family Hx of Mental/Behavioral Disorders
 ;;^UTILITY(U,$J,358.3,20244,1,4,0)
 ;;=4^Z81.8
 ;;^UTILITY(U,$J,358.3,20244,2)
 ;;=^5063363
 ;;^UTILITY(U,$J,358.3,20245,0)
 ;;=Z82.3^^84^930^49
 ;;^UTILITY(U,$J,358.3,20245,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20245,1,3,0)
 ;;=3^Family Hx of Stroke
 ;;^UTILITY(U,$J,358.3,20245,1,4,0)
 ;;=4^Z82.3
 ;;^UTILITY(U,$J,358.3,20245,2)
 ;;=^5063367
 ;;^UTILITY(U,$J,358.3,20246,0)
 ;;=Z82.49^^84^930^31
 ;;^UTILITY(U,$J,358.3,20246,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20246,1,3,0)
 ;;=3^Family Hx of Ischemic Heart Disease/Circulatory System
 ;;^UTILITY(U,$J,358.3,20246,1,4,0)
 ;;=4^Z82.49
 ;;^UTILITY(U,$J,358.3,20246,2)
 ;;=^5063369
 ;;^UTILITY(U,$J,358.3,20247,0)
 ;;=Z82.5^^84^930^22
 ;;^UTILITY(U,$J,358.3,20247,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20247,1,3,0)
 ;;=3^Family Hx of Asthma/Chronic Lower Respiratory Diseases
 ;;^UTILITY(U,$J,358.3,20247,1,4,0)
 ;;=4^Z82.5
 ;;^UTILITY(U,$J,358.3,20247,2)
 ;;=^5063370
 ;;^UTILITY(U,$J,358.3,20248,0)
 ;;=Z82.61^^84^930^21
 ;;^UTILITY(U,$J,358.3,20248,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20248,1,3,0)
 ;;=3^Family Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,20248,1,4,0)
 ;;=4^Z82.61
 ;;^UTILITY(U,$J,358.3,20248,2)
 ;;=^5063371
 ;;^UTILITY(U,$J,358.3,20249,0)
 ;;=Z82.69^^84^930^44
 ;;^UTILITY(U,$J,358.3,20249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20249,1,3,0)
 ;;=3^Family Hx of Musculoskeletal System/Connective Tissue
 ;;^UTILITY(U,$J,358.3,20249,1,4,0)
 ;;=4^Z82.69
 ;;^UTILITY(U,$J,358.3,20249,2)
 ;;=^5063373
 ;;^UTILITY(U,$J,358.3,20250,0)
 ;;=Z83.3^^84^930^28
 ;;^UTILITY(U,$J,358.3,20250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20250,1,3,0)
 ;;=3^Family Hx of Diabetes Mellitus
 ;;^UTILITY(U,$J,358.3,20250,1,4,0)
 ;;=4^Z83.3
 ;;^UTILITY(U,$J,358.3,20250,2)
 ;;=^5063379
 ;;^UTILITY(U,$J,358.3,20251,0)
 ;;=Z83.2^^84^930^24
 ;;^UTILITY(U,$J,358.3,20251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20251,1,3,0)
 ;;=3^Family Hx of Blood/Immune Mechanism Diseases
 ;;^UTILITY(U,$J,358.3,20251,1,4,0)
 ;;=4^Z83.2
 ;;^UTILITY(U,$J,358.3,20251,2)
 ;;=^5063378
 ;;^UTILITY(U,$J,358.3,20252,0)
 ;;=Z82.71^^84^930^47
 ;;^UTILITY(U,$J,358.3,20252,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20252,1,3,0)
 ;;=3^Family Hx of Polycystic Kidney
 ;;^UTILITY(U,$J,358.3,20252,1,4,0)
 ;;=4^Z82.71
 ;;^UTILITY(U,$J,358.3,20252,2)
 ;;=^321531
 ;;^UTILITY(U,$J,358.3,20253,0)
 ;;=Z82.1^^84^930^23
 ;;^UTILITY(U,$J,358.3,20253,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20253,1,3,0)
 ;;=3^Family Hx of Blindness/Visual Loss
